All In MedTech

Device Trial Radar · NCT06948591

BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures

Real World Evaluation of the Safety and Effectiveness of BioBrace® Augmentation in Anterior Cruciate Ligament (ACL) Reconstruction Procedures

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Apr 8, 2025

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
CONMED CorporationPublic (CNMD)
Sponsor type
Industry
First posted
Apr 29, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 14 years, up to 70 years

Summary

As written by the sponsor on the registry.

This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.

Conditions

  • ACL Tears

Interventions

  • Anterior cruciate ligament reconstruction with BioBrace® augmentationDevice

    An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.

  • Arthroscopic anterior cruciate ligament reconstructionProcedure

    An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in FunctionTime frame: 3 years post-op
  2. Adverse EventsTime frame: Baseline, 6-months, 1-, 2-, and 3-years post-op

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ConMed

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.